⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SEPN News
Septerna, Inc. Common Stock
Septerna to Present at Bank of America Securities Health Care Conference
globenewswire.com
SEPN
Form 8-K
sec.gov
SEPN
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
globenewswire.com
SEPN
Form 8-K
sec.gov
SEPN
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
SEPN
Form 8-K
sec.gov
SEPN
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
globenewswire.com
SEPN
Septerna to Present at TD Cowen 46th Annual Health Care Conference
globenewswire.com
SEPN
Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
SEPN
Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting
globenewswire.com
SEPN